Polaris Genomics
Gaithersburg
About Polaris Genomics
Polaris Genomics is mapping molecular biomarkers to chart a new course for objective mental health diagnostics and novel therapeutics. Polaris Genomics identifies genomic biomarkers to support the development of psychiatric drugs and clinical tools. The company's genomics-based ADAPT Platform™ curates information on biologically-relevant gene network pathways indicated in neuropsychiatric conditions ’ including anxiety, depression, alcohol/substance use disorder, ADHD, PTSD, and TBI (ADAPT). The ADAPT Platform™ comprises: 1. targeted neuropsychiatric gene panel, which contains 1000+ transcriptomic biomarkers related to known system pathways in neuropsychiatric conditions; 2. deep analytics (AI/ML) engine; and 3. expanding data lake and sample repository. ADAPT has identified transcriptomic biomarkers for PTSD, resulting in the first-of-its-kind clinical blood test for PTSD screening, Polaris' PTS-ID™.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $5.5M
- Funding stage: Seed
- Last round: Debt Financing (Aug 2025)
- Website: polarisgenomics.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Biotechnology, Clinical Trials, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/polaris-genomics-18254 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.